RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.
Patel, S., Webster, J.D., Varfolomeev, E., Kwon, Y.C., Cheng, J.H., Zhang, J., Dugger, D.L., Wickliffe, K.E., Maltzman, A., Sujatha-Bhaskar, S., Bir Kohli, P., Ramaswamy, S., Deshmukh, G., Liederer, B.M., Fong, R., Hamilton, G., Lupardus, P., Caplazi, P., Lee, W.P., van Lookeren Campagne, M., Johnson, A., McKenzie, B.S., Junttila, M.R., Newton, K., Vucic, D.(2020) Cell Death Differ 27: 161-175
- PubMed: 31101885 
- DOI: 10.1038/s41418-019-0347-0
- Primary Citation of Related Structures:  
6NYH - PubMed Abstract: 
The kinase RIP1 acts in multiple signaling pathways to regulate inflammatory responses and it can trigger both apoptosis and necroptosis. Its kinase activity has been implicated in a range of inflammatory, neurodegenerative, and oncogenic diseases. Here, we explore the effect of inhibiting RIP1 genetically, using knock-in mice that express catalytically inactive RIP1 D138N, or pharmacologically, using the murine-potent inhibitor GNE684 ...